From rising anal cancer rates to AI-driven colonoscopy prep, 2024 saw a wave of advancements and pressing debates in gastroenterology and hepatology. Experts weighed in on FDA approvals, including Rezdiffra for MASH and Shield—the first blood test for CRC screening—while addressing trends like the “sober curious” movement and the alarming rise in metastatic stomach cancer among young adults. As AI chatbots and noninvasive diagnostics gained traction, questions about accessibility and effectiveness lingered.
Keep Reading
Add A Comment